Physician profile
Hugh Ratchford Black
NPI 1427164904
$2,577.29
in general payments reported to CMS, 2019-2025
30 companies · $938 in 2025
The $938 reported for 2025 was more than what 87% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $75.09 · 2021: $200 · 2022: $268 · 2023: $217 · 2024: $651 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $960.14 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $340.49 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $247.53 | 2019-2025 | |
| Integra Lifesciences Corporation | $150.00 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Aerin Medical INC. | $118.54 | 2024 | |
| Kaleo, INC. | $105.59 | 2019-2024 | Auvi-Q |
| Abbvie INC. | $72.28 | 2019-2021 | |
| Insmed, INC. | $61.16 | 2020 | |
| Genentech USA, INC. | $50.19 | 2024-2025 | Xolair |
| Azurity Pharmaceuticals, INC. | $48.28 | 2025 | Alvesco |
| Pfizer INC. | $42.70 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.06 | 2025 | Glassia |
| Glaxosmithkline, LLC. | $37.06 | 2025 | Shingrix, Arexvy, Nucala |
| Merck Sharp & Dohme LLC | $35.94 | 2021-2023 | |
| Philips North America LLC | $32.46 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $29.69 | 2019-2022 | |
| Csl Behring | $24.29 | 2022 | |
| Siemens Medical Solutions USA, INC. | $20.69 | 2025 | Immulite 1000 Immunoassay System |
| Ars Pharmaceuticals Operations, INC. | $20.04 | 2025 | Neffy |
| Mylan Specialty L.P. | $19.95 | 2023 | Yupelri |
| Uswm, LLC | $19.00 | 2021 | |
| Ethicon US, LLC | $18.21 | 2022 | |
| Covis Pharma Gmbh | $15.30 | 2021 | |
| Hikma Pharmaceuticals USA | $14.95 | 2022 | |
| Phadia US INC. | $14.54 | 2025 | Immunocap |
| Amgen INC. | $14.46 | 2025 | Tezspire |
| Aimmune Therapeutics, INC. | $13.46 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.29 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.